The ICIs investigated in myeloid malignancies include those targeting T-cell checkpoints PD-1 [63], PD-L1 [64], and CTLA-4 [63], as well as the macrophage checkpoint CD47 [65]. The gene discussed is PDCD1; the disease is myeloid neoplasm.